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Abstract
Murine monoclonal antibody V5B2 which specifically recognizes the pathogenic form of the prion protein represents a
potentially valuable tool in diagnostics or therapy of prion diseases. As murine antibodies elicit immune response in human,
only modified forms can be used for therapeutic applications. We humanized a single-chain V5B2 antibody using variable
domain resurfacing approach guided by computer modelling. Design based on sequence alignments and computer
modelling resulted in a humanized version bearing 13 mutations compared to initial murine scFv. The humanized scFv was
expressed in a dedicated bacterial system and purified by metal-affinity chromatography. Unaltered binding affinity to the
original antigen was demonstrated by ELISA and maintained binding specificity was proved by Western blotting and
immunohistochemistry. Since monoclonal antibodies against prion protein can antagonize prion propagation, humanized
scFv specific for the pathogenic form of the prion protein might become a potential therapeutic reagent.
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Introduction
For more than thirty years murine monoclonal antibodies have
been routinely produced by the Ko ¨hler and Milstein method [1].
Such mAbs are widely used in clinical diagnostics, but are not
appropriate for human therapy, since they elicit an immune
response, referred to as human anti-mouse antibodies (HAMA)
[2]. With the advances in molecular genetics and DNA technology
less immunogenic recombinant antibodies with binding properties
similar to murine Abs can be designed. The first attempt to
minimize immunogenicity of murine antibodies was chimerization
[3] where murine variable regions were fused to human constant
regions. However, chimeric antibodies can still trigger HACA
(human anti-chimeric antibodies) response. To further reduce the
immunogenicity, CDR (complementarity determining regions)
grafting was developed [4] in which hypervariable regions of a
murine antibody are introduced into a human antibody using
genetic manipulation. Although such antibodies were proved to be
less immunogenic, they frequently exhibited reduced affinity
compared to the parent murine antibody. As an alternative to
CDR grafting, resurfacing was developed, where only surface
residues of variable regions are replaced with those found in
human antibodies [5]. It was based on the premise that the human
immune response is directed mainly to the surface residues. With
unchanged amino acids in the core of variable regions,
conformation of the antigen binding site is less likely to be
disturbed, thus the specificity and affinity of the parent antibody
should be maintained.
In 1986 the first murine monoclonal antibody (mAb) was
approved for clinical use by the Food and Drug Administration
and since then more than 20 mAbs have been approved for
therapeutic applications in humans. Humanized antibodies
represent more than a half of them [6,7].
Antibody-based immunotherapy might represent an effective
treatment for several diseases [8] including conformational
disorders like transmissible spongiform encephalopathies (TSEs)
[9]. The hallmark of these diseases is the conformational change of
the host-encoded cellular prion protein (PrP
C) into the pathogenic
isoform (PrP
Sc), named prion [10]. Despite all the effort put into
research of prion diseases, some basic mechanisms of the prion
neurotoxicity and pathogenesis remain unclear. This is one of the
reasons why neither therapy for TSE nor tools for an early pre
mortem diagnostics of asymptomatic prion-infected individuals are
available at the moment. Numerous compounds were tested for
their antiprion activity [for review see 11] and the use of
monoclonal antibodies seems to be one of the most promising
therapeutic approaches. Since the first successful production of
high-affinity anti-prion protein (PrP) antibodies in PrP-knockout
mice [12], several mAbs against PrP have been produced.
However, only a few mAbs capable to distinguish PrP
Sc form
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C have beed reported [13,14,15,16,17,18]. One of them is
mAb V5B2, prepared against the C-terminal peptide P1 of the
human PrP [13]. Many reports have shown that some of murine
anti-PrP mAbs that did not distinguish between PrP
C and PrP
Sc
were nevertheless able to prevent prion infection in vitro
[19,20,21,22], and a few studies also demonstrated in vivo anti-
prion action of such mAbs [9,23,24]. However, as PrP
C is
normally expressed on the surface of a variety of cell types, doubts
about possibly deleterious systemic blocking of PrP
C by such
isoform-nonspecific mAbs have emerged [19,25]. A range of
antibody fragments with anti-prion activity has been derived from
murine anti-PrP antibodies [26] and a few antibody fragments
were already isolated from combinatorial phage display libraries
expressing human scFvs [27,28].
V5B2 is the PrP
Sc-specific IgG1 monoclonal antibody prepared
against a synthetic peptide P1, chosen from the C-terminus of the
human PrP. It was shown that it distinguishes between brain tissue
samples from CJD (Creutzfeldt–Jakob disease) - affected and non-
CJD-affected patients reacting only with the native PrP
Sc deposits
in immunohistochemical assays [13]. Because of these properties,
it has a great potential to be used in immunodiagnostic procedures
or prion research. It was already used to induce anti-idiotypic
response in mice and chicken in order to produce anti-idiotypic
antibodies, which represented a new experimental approach in
prion research [29]. To better understand the narrow selectivity of
V5B2, interaction between the antibody and P1 peptide was
investigated [30], but only the most recent studies revealed that
V5B2 selectively recognizes the newly discovered C-terminally
truncated PrP, named PrP226* (S. Koren, personal commun.). To
prepare a more suitable form of V5B2 for further immunother-
apeutic development, recombinant single-chain antibody frag-
ments have been derived from the mAb [31]. However, murine
antibody fragments are immunogenic, which is the major obstacle
to their clinical application. For that reason, we decided to reduce
its immunogenicity by humanization.
The present data describe the humanization of the antibody
single-chain fragment (scFv) V5B2 and its characterization. To
our knowledge, this is the first report of an anti-PrP mAb being
humanized. We rationally designed four variants of humanized
scFvs V5B2 by resurfacing of variable regions guided by
computer modelling. By site-directed mutagenesis, human amino
acid residues were stepwise introduced into murine variable
regions. After being produced in E. coli using pMD204 expression
vector [32], humanized antibody fragments were purified from
the periplasm and their antigen-binding properties were analysed.
The optimized construct was a scFv with 13 mutations
introduced at key positions in the structure, which retained
stability, binding specificity and affinity of the parent antibody.
We believe that the recombinant humanized scFv with preserved
functional properties of V5B2 could be used for designing new
compounds with potentially diagnostic and therapeutic anti-prion
properties.
Materials and Methods
1. Ethics statement
Approval for research involving human material has been
obtained from the Slovenian National Medical Ethics Committee
with decision dated January 15, 2008. Post mortem brain tissue of a
patient who was clinically suspected for CJD was analyzed by
immunohistochemistry without patient’s consent because such
analysis is obligatory by a ministerial decree in purpose of TSE
surveillance (Official Gazzette of the Republic of Slovenia, 2/
2001).
2. Reagents and strains
DNA restriction and modification enzymes were from Fermen-
tas, except Pfx50 polymerase (Invitrogen) and Taq DNA ligase
(New England BioLabs). Molecular weight standards and DNA
purification kits were obtained from Fermentas as well. Oligonu-
cleotides were from Invitrogen. For all cloning experiments we
used E. coli strain DH5a. For expression, BL21[DE3] strain was
used. Preparation of recombinant full length human prion protein
HuPrP(23–231) and its fragment HuPrP(23–226), also named
PrP226*, was performed in the laboratory of Dr. Giuseppe
Legname (Italian Institute of Technology - SISSA, Trieste, Italy).
Synthetic peptides derived from the human prion protein (P1,
amino acids 214–226: CITQYERESQAYY; P1Q, amino acids
214–227: CITQYERESQAYYQ) were purchased from JPT
Peptide Technologies. Mouse mAb 6H4, recognizing the sequence
DYEDRYYRE (human PrP residues 144–152) was purchased
from Prionics, Zurich, Switzerland. Sections of paraformaldehyde-
fixed, paraffin-embedded human cerebellar tissue samples from a
patient with sporadic CJD (sCJD) with kuru plaques and synaptic
immunohistochemical type of prion deposition pattern were used
in the study. Tissue samples for immunohistochemistry analyses
were obtained from the Institute of Pathology, University of
Ljubljana Medical Faculty.
3. Monoclonal antibody V5B2 and murine scFv V5B2
Preparation of a hybridoma cell line secreting a monoclonal
IgG1 directed against the P1 peptide of human prion protein has
been reported previously [13]. Total RNA was isolated from
hybridoma cells as described [33]. Complete coding regions of
both variable domains were obtained and single-chain antibody
fragments were prepared in bacterial cells as described [31].
4. V5B2 framework analysis: Humanization design
Immunogenicity of murine antibody was minimized by
humanization through antibody variable domains resurfacing.
On the basis of sequence alignments framework residues in the
murine antibody that are rare in human antibodies were identified
and replaced with those usually found in structurally related
human antibodies. Ten murine and ten human antibody
sequences with highest identity to V5B2 were chosen from the
3D structure database (Protein Data Bank) [34]. Then, surface
residues in antibody variable (Fv) domains (light chain and heavy
chain variable domains (Vl + Vh)) of these selected antibodies were
determined by calculation of residue solvent accessibilities using
software Swiss-PdbViewer [35]. Residues with relative accessibility
greater than 30% were defined as surface amino acids. Sequences
of variable domains of murine antibody V5B2 were aligned with
sequences of selected antibodies of known structure to identify
homologous surface positions. The first set of highly homologous
surface framework residues was selected from human sequences
and was compared to those in the murine V5B2 in order to
humanize them. Second, a set of framework residues that
appeared to be on the surface of several selected human antibodies
was identified and human residues at those positions were chosen
to be introduced in the V5B2. Third, some framework non-surface
residues that appeared to be highly conserved in human antibodies
but were different in V5B2 were candidates for replacement.
Fourth, Ser43 in Vl of V5B2 located at the Vl/Vh interface
differed from the human consensus residue for this position and
was thus also chosen for replacement. We prepared a structure
model of V5B2 Fv to analyse the influence of each mutation on
V5B2 CDRs conformation. All variants of V5B2 were modelled
and tested in silico for antigen binding. The humanized sequence of
V5B2 variable domains was compared to human VH subgroups
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similarity were calculated by ClustalW [37]. Detailed description
of the stepwise humanization process is presented in Results and
amino acid sequence alignment is shown in Figure 1.
5. Molecular modelling of V5B2 variable domains
Molecular model of the murine V5B2 Fv was generated via
homology-based modelling using a computer program Model-
ler9v1 [38]. Nine antibody structures with the highest sequence
identity with the V5B2 were selected from the PDB database and
used as templates to generate a model. Three of the selected
structures were used as templates for Vl (identity 68–92%), five of
them as templates for Vh (identity 66–86%) and one structure was
used as a template for proper orientation of variable domains in
Fv. First, ten basic models were build, followed by loop refinement
for L3 and H3 loops, which resulted in a total of fifty models. The
model with the lowest modeller objective function and optimal
DOPE-score was selected as the final model. The quality of the
model was analysed by a range of tools for evaluation of
crystallographic models. V5B2 Fv model of is shown in Figure 2.
6. Site-directed mutagenesis
All mutations were introduced into V5B2 variable domains
using the mutagenesis by incorporation of a phosphorylated
oligonucleotide during polymerase chain reaction (PCR) amplifi-
cation essentially as described [39]. Briefly, three primers (forward,
reverse and mutagenic) were used to generate each mutant: first,
the mutagenic oligonucleotide was phosphorylated using T4
polynucleotide kinase and added directly to the amplification
reaction together with thermostable DNA ligase. After PCR, two
products were observed. The full-length product was purified,
ligated into the cloning vector pJET1/blunt (Fermentas) and
sequenced (Macrogen).
7. Construction, expression and purification of
humanized scFvs
Humanized scFvs were produced as described for murine scFvs
V5B2 [31]. Mutated coding regions for heavy chain variable
domain (Vh) and light chain variable domain (Vl) were amplified
by PCR using specific primers. Vl and Vh were inserted into
pMD204 expression vector between NruI and EcoRI and XhoI and
HindIII restriction sites, respectively. The 15-amino acid linker
(Gly4Ser)3 was obtained from a pair of phosphorylated oligonu-
cleotides and the cassette was used to connect the C-terminus of Vl
to the N-terminus of Vh. Five final vectors, named pMD204-
LLHmut1, pMD204-LLHmut2, pMD204-LLHmut3, pMD204-
LLHmut4 and pMD204-LLHhum, were constructed. After
transformation of E. coli DH5a, vector isolation and sequencing
of the inserts, recombinant vectors were used for E. coli
BL21[DE3] transformation. Transformants were grown in M9
minimal medium supplemented with 2% glucose, 0.5% peptone,
and chloramphenicol (50 mg/ml) at 37uC and 250 rpm. Isopropyl
b-D-1-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.5 mM as the OD550 of cell culture reached
1.0 and cell growth was continued for 12–16 h at 16uC and
200 rpm. Cells were harvested and resuspended in a small volume
of 50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, sonicated and
pelleted by centrifugation at 15500 g for 30 min and 4uC.
Supernatant was collected as soluble fraction. Cell lysates were
prepared for electrophoresis as described [31].
Figure 1. Amino acid sequence alignments. Alignment of light chain (Vl) and heavy chain (Vh) variable regions of the murine V5B2 scFv
(moScFv), two humanized (LLHmut1, LLHmut2) and final humanized version (huScFv) of mAb V5B2 with human consensus sequences of light chain k
subgroup I (HhumkI) and heavy chain subgroup III (HumIII). The dashes represent unchanged amino acids. CDRs are underlined. Amino acids are
numbered according to Kabat [36].
doi:10.1371/journal.pone.0015783.g001
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chromatography (IMAC). The soluble fraction was loaded onto the
column and washed with the washing buffer (50 mM sodium
phosphate, pH 8.0, 0.3 M NaCl, 10 mM imidazole). The recom-
binant scFv was eluted with the elution buffer (50 mM sodium
phosphate, pH 8.0, 0.3 M NaCl, 250 mM imidazole). Collected
fractions were pooled, dialyzed against PBS and analysed on 15%
polyacrylamide slab gels according to Laemmli [40] under reducing
conditions. Anigen-binding properties of recombinant scFvs were
analysed by enzyme-linked immunosorbent assay (ELISA), Western
blotting and immunohistochemistry (IHC).
8. ELISA
Microtiter plates were coated overnight at 4uC with 50 mlo f
5 mg/ml peptide P1 or P1Q in 50 mM carbonate/bicarbonate
buffer pH 9.6. After blocking with 1% bovine serum albumin in
10 mM phosphate buffer (pH 7.2) and washing, purified scFvs
(ten-fold serial dilutions, at concentrations ranging from 300 mg/
ml to 300 pg/ml) were added and incubated for 1 h at 37uC.
Single-chain Fvs were detected using primary mouse anti-His6
antibodies (Roche) and secondary goat anti-mouse IgG antibodies
conjugated with horseradish peroxidase (HRP) (Jackson Immu-
noResearch). Incubation was performed at 37uC for 1 h.
Peroxidase activity was detected using the peroxidase substrate
ABTS (2,29-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (Sig-
ma). After 20-min incubation at 37uC, absorbance at 405 nm was
measured. The absorbance signal at 405 nm versus the total
concentration of scFv added to the wells was plotted. Experimental
data were fitted to equation S=Smax*Ab/(Ab+KD).
9. Immunohistochemistry
Tissue samples were immersed in 96% formic acid for 1 h after
fixing in paraformaldehyde. Sections were deparaffinized and
pretreated for optimal antigen retrieval by 30 min autoclaving at
121uC in distilled water, followed by a 5 min incubation in 96%
formic acid. Pretreated sections were blocked in 1% bovine serum
albumin solution for 20 min at room temperature (RT). They were
subsequently incubated overnight with primary antibodies (5 ml/ml
V5B2 and 100 mg/ml mouse LLH scFv (moScFv) or humanized
scFv (huScFv)) at RT in the moist chamber. Primary antibody
concentrations were chosen from ELISA titration curves in order to
obtain optimal antigen binding. Brain tissue sections incubated with
scFvs were washed and incubated for 3 h with anti-His6 antibodies
(0.3 ug/ml, Roche) at RT. Finally, all sections were washed and
incubated for 1.5 h with anti-mouse HRP-labelled antibodies
(diluted 1:1000, Jackson ImmunoResearch) at RT. After thorough
rinsing, sections were developed in 3,39-diaminodbenzidine (DAB)
chromogen for 5 min. Brain tissue counterstaining was obtained by
2 min immersion of sections in Mayer’s hematoxylin.
10. SDS-PAGE and immunoblotting
Cell lysates were incubated for 5 min at 95uCi n5 6 SDS
loading buffer containing 25% 2-mercaptoethanol. Samples were
loaded on 12% SDS-Tris-glycine polyacrylamide gels and
electrophoresed for 90 minutes at 130 V. Proteins were blotted
onto 0.2 mm nitrocellulose membranes (Protran BA83, Whatman)
at 210 mA for 70 min. Membranes were blocked with 5% non-fat
milk at 4uC overnight, washed and then incubated with primary
mAb V5B2 (5 mg/ml in 1% non-fat milk solution), 6H4 (0.2 mg/
ml in 1% non-fat milk solution), moScFv or huScFv (35 ug/ml 1%
non-fat milk solution) for 90 minutes with shaking at RT. After
washing, membranes incubated with scFvs were incubated with
anti-His6 antibodies (0.3 mg/ml, Roche) for 90 min with shaking
at RT, then with HRP-labelled anti-mouse secondary antibody
(Jackson ImmunoResearch; 1:5000 in 1% skimmed milk solution)
at room temperature for 90 minutes, and washed again. Reaction
was detected using Amersham ECL Western blotting detection
reagents.
Results
1. Humanization guided by computer modelling
Humanization by antibody variable domain resurfacing was
chosen for minimization of immunogenicity of the murine
Figure 2. Molecular model of the Fv V5B2. CDR loop residues are coloured pink. Non-conserved surface residues are shown in yellow. Mutations
introduced into the huScFv are bolded.
doi:10.1371/journal.pone.0015783.g002
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determined based on the sequence alignment of V5B2 with other
murine and human sequences with the identities ranging from
87% to 64% for Vh and 92% to 69% for Vl. Surface-accessible
residues of Fv regions were defined as those with relative solvent
accessibility $30%. Fifteen such residues in Vl and thirteen
residues in Vh were determined on the surface of the V5B2
framework, which was consistent with results obtained by
statistical analysis of a database of murine and human immuno-
globulin sequences described in the Pedersen study [41]. Seven of
these residues (4 in Vl and 3 in Vh) were non-conserved and were
chosen to be replaced with the human consensus residues for these
positions. In addition, V5B2 model Fv (Fig. 2) revealed that L17
residue might be considered as surface accessible, therefore
together eight replacements were made in the first version of
humanized V5B2 scFv, named LLHmut1. With further investi-
gation, additional 14 residues were identified on the surface of
each variable region of several structurally related human
antibodies. Analysis on the V5B2 model revealed that replacement
of 4 non-conserved residues in Vl and 5 non-conserved residues in
Vh should not significantly alter the CDRs conformation. These 9
replacements were thus additionally introduced in the second
version of scFv V5B2, named LLHmut2. The basic goal of the
resurfacing is replacement of only surface murine residues,
retaining the core of variable regions as undisturbed as possible
to avoid possible conformational perturbances of the CDRs. Since
our aim was to make the murine antibody V5B2 as human-like as
possible, we analysed V5B2 sequence further. Additional highly
conserved residues were identified in the core of structurally
related human antibody variable regions. Eleven residues in Fv
V5B2 (5 in the core of Vl and 6 in the Vh) differed from human
conserved amino acids at these positions. The introduction of
human residues at selected positions in the murine model of V5B2
has not revealed major disturbances in the conformation of CDRs,
so the third version of humanized scFv V5B2, LLHmut3, was
designed. Finally, the influence of Ser43 at the Vl/Vh interface
between murine and human antibody sequences was investigated.
Since Ala is conserved residue for L43 position in human
antibodies, murine Ser was replaced by Ala in the fourth version
of humanized V5B2, named LLHmut4. All four humanized
versions of V5B2 were prepared as recombinant proteins and
analysed for antigen binding. Since LLHhum2, LLHmut3 and
LLHmut4 all showed altered binding to P1, intermediate variants
between LLHmut1 and LLHmut2 were prepared in the next
round of humanization. The final humanized V5B2, named
huScFv, contained 9 mutations in Vl and 4 mutations in Vh and
had binding properties similar to mouse scFv directed against the
same antigen. In order to preserve strong binding activity, 6
murine residues in Vl and 9 in Vh were maintained in the
frameworks. Sequences of murine and humanized V5B2 variable
regions aligned with human consensus sequences of heavy chain
subgroup III (HumIII) and light chain k subgroup I (HhumkI) are
shown in Figure 1. Based on amino acid sequence alignment,
identity and similarity scores of the V5B2 humanized variable
domain frameworks with HumkI and HumIII human antibody
frameworks [36] were calculated by ClustalW. In silico analysis
showed that amino acid sequence of huScFv appeared to be highly
similar to amino acid sequence of human antibodies with most of
the differences in the FR3 region of the Vh domain. The results
are shown in Table 1.
2. Production of humanized scFvs
Complementary DNA encoding for V5B2 variable domains was
derived from hybridoma cells mRNA and both chain orientations
of murine scFvs V5B2 have been produced [31]. LLH chain
orientation (scFv in Vl-linker-Vh chain arrangement) retained
strong binding to the antigen [31], therefore the same orientation
was chosen for the humanized V5B2 scFvs. All humanized scFvs
were expressed in E. coli periplasm using the expression vector
pMD204, specially developed for construction and production of
fusion proteins [32]. The scFv-encoding constructs derived from
variable regions of V5B2 linked via a short linker (G4S)3 were
inserted into the pMD204 expression vector, in frame with the
ompA signal sequence and upstream of the His10 tag. E. coli
BL21[DE3] cells containing pMD204-scFv plasmid were induced
by IPTG and then grown at 16uC for up to 18 h, since lowering
incubation temperature improved the ratio of soluble to insoluble
recombinant antibody fragments as already shown for murine
scFvs [31]. The yield of recombinant proteins was similar for all
humanized variants and was comparable to the production of
murine scFv in LLH orientation. SDS-PAGE analyses of cell
lysates revealed the presence of a band with the approximate
molecular weight of 30,000 after induction, i.e. as expected for the
scFv (Figure 3). No significant differences were observed in cell
growth, protein production, purification or electrophoretic
mobility between murine and humanized scFvs.
Nickel affinity chromatography was used for protein purifica-
tions, since His10 tag was added to the C-terminus of all
recombinant scFvs. Most of contaminating proteins were elimi-
nated from the soluble fraction of cell lysates by washing the
column with a buffer containing 10 mM imidazole. Single-chain
Fvs were eluted from the column with a buffer containing
250 mM imidazole. The final yield of purified scFvs was estimated
at 0.5–1 mg per litre bacterial culture with purity greater than
90%. Purified scFvs were first analysed by SDS-PAGE (Fig. 3), and
then tested for antigen binding by ELISA, Western blotting and
IHC.
3. Antigen-binding properties
The ability of humanized variants of scFv V5B2 to bind peptide
P1 was tested by ELISA (Figure 4). LLHmut1 showed similar
binding to P1 peptide as moScFv, while other three humanized
variants successfully bound P1 only when ELISA was performed at
lower temperature (e.g. 16uC) (data not shown). Since diagnostic
and therapeutic reagent should retain their stability and activity at
Table 1. Identity and similarity scores of the V5B2 humanized
variable domain frameworks with HhumkI and HumIII human
antibody frameworks calculated by ClustalW.
Domain Identity (X/Y) Identity (%) Similarity (%)
Vh
FR1 22/23 95.65 100
FR2 14/14 100 100
FR3 20/32 62.50 90.63
FR4 10/10 100 100
Vl
FR1 23/23 100 100
FR2 13/15 86.67 100
FR3 27/30 90 90
FR4 11/12 91.66 100
X is the number of identical framework residues; Y is the total number of
framework residues.
doi:10.1371/journal.pone.0015783.t001
Humanization of PrPSc-Specific Single-Chain Fv
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15783physiological temperatures, a variant between LLHmut1 and
LLHmut2 with adequate binding properties was prepared.
Binding affinity of the final humanized single-chain antibody
fragment (V5B2 huScFv) was comparable to the affinity of
moScFv V5B2. In addition, both scFvs, moScFv and huScFv,
recognized the peptide P1, whereas no binding was observed when
peptide P1Q (P1 prolonged for a single Glu residue at the C-
terminus) was used as an antigen in ELISA (Figure 4). Similar
binding specificity was shown for the parent antibody V5B2 [13].
Further, we demonstrated by immunoblotting that both murine
and humanized scFvs efficiently labelled recombinant human
PrP23–226, named PrP226* (S. Koren, personal commun.), but
not the full-length PrP, and therefore retained the characteristic
binding properties of V5B2 (Figure 5). The results were compared
to mAb 6H4 binding, which does not distinguish between cellular
and pathological isform of PrP [16]. In contrast to V5B2 antibody
forms, it labelled PrP226* as well as full-length PrP (Figure 5).
Finally, we performed IHC on a tissue sample of a sCJD case with
kuru plaque and synaptic pattern of PrP
Sc deposition with
moScFv, huScFv or whole V5B2 antibodies. The results show
that both scFvs specifically label kuru plaque PrP
Sc deposits, but
were unable to label the fine synaptic PrP
Sc deposition pattern,
both finely labelled with V5B2 antibody (Figure 6).
Discussion
Single-chain Fvs are much smaller than whole antibodies,
besides they do not require glycosylation and can be produced in a
bacterial expression system. Such production is simpler, faster and
significantly reduces production costs [42]. Therefore, instead of
full-length V5B2 antibody the scFv form was chosen to be
humanized and produced.
Wehavesuccessfullyhumanizedasingle-chainantibodyfragment
of the murine monoclonal antibody V5B2, specific for PrP
Sc-
fragment associated with prion-infected samples [13]. We construct-
ed over 30 scFvs on the DNA level and expressed, purified and
examined a total of 14 humanized constructs: 4 for basic stages and
10 intermediates between different stages in search of destabilizing
mutations. Construct with optimal binding properties and maximal
possible amino acid replacements was denoted huScFv V5B2. Our
humanization approach by resurfacing differed from the conven-
tional one, as beside surface residues we tried to replace some
residues in the core of variable regions as well. Non-conserved
framework surface residues, which were not deemed too close to
CDRs were replaced, but experimental analyses revealed that of
these, 6 positions in Vl and 10 positions in Vh substantially affected
antibody interaction with the antigen. For that reason a compromise
between potential immunogenicity and retained binding specificity
had to be made. Finally, 13 murine residues were replaced in the
moScFv V5B2 to prepare a huScFv V5B2, which retained the
significant ability to discriminate between CJD-affected and normal
brain tissue. Nevertheless, the amino acid sequence of huScFv V5B2
shows high similarity with the human heavy chain subgroup III and
light chain k subgroup I consensus sequences.
In the process of humanization a computer model of antibody
variabledomainsisoftenbuilttohelp designthehumanized form.It
is used for prediction of possible influence of mutations on CDR
conformations, which usually results in loss of antibody binding
affinity or even specificity. Several reports showed that analysis of a
computer model actually helped to avoid problems with the affinity
reduction, which is particularly typical for CD-grafting [43,44,45].
Moreover, it was demonstrated that during humanization antibody
affinity could even be improved when the humanized form is
carefully designed on the basis of a precise analysis of structural
models [46]. In our case, the structural model of the Fv V5B2
helped to determine framework surface residues of the V5B2, but it
did not predict negative impact of several replacements we have
introduced.Itwashoweverreasonabletoexpectthatnotallplanned
mutations could be introduced into variable domains without
disturbing the structure of the antigen-binding site and influencing
the binding. For that reason, several intermediate variants were
prepared and tested for antigen-binding activity.
A few resurfaced scFvs have been reported in the literature,
generally containing from six to ten replacements [e.g. 45,47,48].
Any additional mutation usually resulted in reduced binding
activity. It was also shown that even a single mutation in the
antibody framework can improve or reduce the expression yield or
binding affinity of a scFv tremendously [49,50,51].
Figure 3. SDS-PAGE analyses of mouse (moScFv) and human-
ized (huScFv) scFv V5B2. Cell lysates were analyzed before (2) and
after (+) IPTG induction, along with purified scFvs (e). Molecular masses
of protein standards in kDa are indicated on the left. Similar
electrophoretic pattern was obtained with all humanized scFv variants.
doi:10.1371/journal.pone.0015783.g003
Figure 4. ELISA analysis of the antigen-binding efficiency of
moScFv and huScFv. The absorbance at 405 nm is plotted against
concentration of antibody fragment added to the wells coated with the
P1 or P1Q peptide. The apparent affinity of moScFv in comparison with
Fab V5B2 has been discussed previously [31].
doi:10.1371/journal.pone.0015783.g004
Humanization of PrPSc-Specific Single-Chain Fv
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15783In our experiments, Western blot analyses indicated that
humanized V5B2 scFv recognized the same epitope on PrP as
the parent V5B2 mAb. When huScFv was assayed by IHC, it
labelled less kuru plaque-like PrP
Sc deposits than V5B2 and failed
to label the synaptic pattern of PrP
Sc deposition, which was clearly
visualized by whole V5B2 mAb. This observation was attributed to
expected reduced affinity of scFvs that hindered the detection of
fine synaptic pattern and small plaques. Our IHC experiment
clearly demonstrated that both murine and humanized form of
scFv retained the ability to label PrP
Sc deposits specifically,
although less potently, which is in agreement with results obtained
by ELISA and immunoblotting.
Even though several antibodies have been resurfaced in the last
decade, their immunogenicity remains undetermined, since no
clinical data on resurfaced antibodies has been published yet [52].
Since the amino acid sequence of the humanized scFv was
carefully designed and was found to be highly similar to human
sequences, we believe that we efficiently removed all major
immunogenic epitopes on the murine antibody. However, the
actual immunogenicity could only be determined in clinical trials.
Immunotherapy based on anti-PrP antibodies is a promising
strategy for the treatment of prion diseases. It has already been
shown that some anti-PrP mAbs can antagonize prion propagation
in vitro and in vivo, but only outside the brain, most likely due to
Figure 5. Western blotting of the recombinant human PrP 23–226 (PrP226*) and of the recombinant human PrP23–231 (HuPrP).
Reaction with the whole mAb V5B2 is compared to reactions with murine scFv (moScFv) and humanized scFv (huScFv) of V5B2. mAb 6H4 was used as
a control antibody. Approximate molecular weights are in kilodaltons.
doi:10.1371/journal.pone.0015783.g005
Figure 6. Immunohistochemistry of the PrP
Sc deposits in the cerebellum of a sCJD patient (upper three figures). Immunolabeling was
performed with whole mAb V5B2, murine scFv (moScFv) and humanized scFv (huScFv) of V5B2. The arrow marks PrP
Sc plaques, while the triangle
marks the diffuse, synaptic PrP
Sc deposition. On the lower three figures immunolabeling was performed on the cerebellum of the CJD negative
patient.
doi:10.1371/journal.pone.0015783.g006
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system.
Single-chain fragments are much smaller than whole antibodies,
but usually they retain specific monovalent antigen-binding affinity
of the parent antibody, with improved pharmacokinetics for tissue
penetration. Antibody fragments have already been reported to be
successfully delivered to the central nervous system by intranasal
administration [53], by virus-mediated gene transfer system [54]
or by re-engineering as fusion proteins with BBB molecular Trojan
horses [55]. Besides, antibody fragments appear to be more
appropriate for TSE treatment than full antibodies, since bivalent
anti-PrP antibodies have been shown to cross-link PrP
C molecules
and trigger neuronal apoptosis in certain neuronal populations
[56]. It was also demonstrated that constant domains are
unnecessary for antiprion effect, since Fab D18 [22], scFv 6H4
[57] and scFv D18 [58] all exhibited antiprion activity. A construct
that targets PrP
Sc specifically could even be more efficient.
Moreover, distinguishing between the pathological and the
normal isoform of PrP is one of the most desirable properties of
diagnostic tools for prion diseases. Based on the existing knowledge
it can be concluded that small molecules, exhibiting high affinity
binding of the pathological PrP isoform, such as our humanized
scFv V5B2, might be a potential therapeutic reagent for TSEs.
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